Testing an Immune Cell Treatment Made From a Person's Own Brain Tumor
Official title: Study of GC101 TIL in Brain Glioma (Soochow2)
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on .
The short version
This trial is testing a treatment that uses immune cells taken from a person's own glioma: A tumor that starts in the glial cells, the support cells of the brain and spinal cord. Gliomas are graded 1 to 4 by how fast they tend to grow. See the glossary.
Read our full plain-language summary
What the trial team says
This study is to investigate the safety and efficacy of tumor infiltrating lymphocyte (TIL) therapy in patients with malignant glioma . Autologous TILs are expanded from tumor resections and infused i.v. into the patient after NMA lymphodepletion treatment with hydroxychloroquine(600mg,single-dose) and cyclophosphamide.
Key facts
- Registry number
- NCT04943913
- Stage of testing
- Early phase 1
- Conditions studied
- Glioma
Where it is running
This trial lists 1 site.
-
Jiangsu
- The Second Affiliated Hospital of Soochow University (Suzhou)
How to use this
Talk to your care team first. They know your history and can tell you whether this trial is worth your time.
Joining a trial is always your choice. A trial is a test, not a proven treatment. Being in one is not a promise that it will help you.
This page is built from the trial's listing on ClinicalTrials.gov, a service of the U.S. National Library of Medicine. That listing is the authority, and it may have changed since we last read it. We do not run this trial and we cannot enroll you in it.